As a Med Honors Top Pharmaceutical Innovator, Pfizer has played a pivotal role in advancing modern medicine through cutting-edge drug development, vaccine innovation, and biopharmaceutical research. Founded in 1849, Pfizer has grown into one of the world’s most influential pharmaceutical companies, delivering life-changing therapies across multiple specialties.

Pfizer is widely known for its groundbreaking work in vaccine development, particularly its mRNA-based COVID-19 vaccine, developed in partnership with BioNTech. As the first FDA-approved mRNA vaccine, it revolutionized global efforts to combat the pandemic and reinforced Pfizer’s position as a leader in infectious disease prevention, building on a legacy that includes vaccines for pneumococcal disease, meningitis, and influenza.

Beyond vaccines, Pfizer is a driving force in oncology, immunology, and cardiovascular medicine, consistently introducing best-in-class therapies. Its oncology portfolio includes Ibrance (palbociclib), a leading treatment for metastatic breast cancer, as well as Bavencio (avelumab) and Lorbrena (lorlatinib), which have expanded treatment options for difficult-to-treat cancers. In immunology, Xeljanz (tofacitinib) has transformed care for autoimmune conditions such as rheumatoid arthritis and ulcerative colitis, while Eliquis (apixaban) remains a cornerstone of stroke prevention and cardiovascular health.

With a relentless commitment to research and innovation, Pfizer continues to develop groundbreaking therapies that shape the future of medicine, earning its place among Med Honors’ most distinguished pharmaceutical leaders.